The vagus nerve is the heart’s primary brake. Through a direct connection to the sinoatrial (SA) node — the heart’s natural pacemaker — the vagus nerve releases acetylcholine, which slows the rate at which the SA node fires. This mechanism, often called the “vagal brake,” is what keeps your resting heart rate well below the SA node’s intrinsic firing rate of around 100 beats per minute. Without vagal input, the heart would beat significantly faster at rest, burning energy the body doesn’t need to spend.
This braking action is not fixed. It adjusts in real time, beat by beat, in response to breathing, posture, stress, and physical demand. When you inhale, vagal output briefly decreases and heart rate rises slightly. When you exhale, vagal output increases and heart rate slows. This phenomenon — respiratory sinus arrhythmia — is the physiological basis for the most commonly used measure of cardiac vagal health: heart rate variability (HRV).
HRV: A Window into Cardiac Vagal Tone
Heart rate variability measures the variation in time between consecutive heartbeats. Higher HRV generally reflects stronger vagal influence on the heart and greater cardiovascular adaptability. Lower HRV indicates reduced vagal tone and a heart that is less responsive to changing demands.
The most vagally specific HRV metric is RMSSD (root mean square of successive differences between heartbeats), which captures beat-to-beat variation driven primarily by the vagus nerve. In frequency-domain analysis, high-frequency (HF) power (0.15–0.40 Hz) reflects the same vagal respiratory modulation. Time-domain measures like SDNN from 24-hour recordings capture both vagal and sympathetic contributions and are the best-validated predictor of cardiovascular outcomes.
A 2025 review in Frontiers in Cardiovascular Medicine examined HRV’s role in cardiovascular risk prediction. The findings were mixed: in post-MI patients, low SDNN consistently predicted higher mortality, and day-to-day instability of HRV predicted death independently of average HRV values. In people without known cardiovascular disease, low HRV was associated with a 32–45% higher risk of a first cardiovascular event. However, HRV’s independent predictive value often diminished after adjusting for established risk factors like ejection fraction. The reviewers concluded that HRV likely complements existing clinical tools rather than replacing them.
One unexpected finding from the MESA cohort study: both very low and very high HRV were associated with increased risk of atrial fibrillation, suggesting a U-shaped relationship rather than the simple “higher is always better” assumption.
Vagal Maneuvers: First-Line Treatment for SVT
Vagal maneuvers are the first-line treatment for stable supraventricular tachycardia (SVT) — episodes where the heart suddenly races at 150–250 beats per minute due to a re-entrant electrical circuit involving the AV node. By sharply increasing vagal output, these maneuvers flood the AV node with acetylcholine, briefly blocking conduction through the re-entrant circuit and terminating the arrhythmia.
The modified Valsalva maneuver (MVM) has emerged as the most effective option. The technique involves blowing hard into a syringe or against resistance for 15 seconds while sitting semi-upright, then immediately lying flat with the legs raised to 45 degrees for 15 seconds. The leg-raise phase produces a surge of venous return to the heart, which triggers a strong vagal reflex.
A 2025 network meta-analysis of 19 randomised controlled trials involving 2,545 adults found the modified Valsalva roughly doubled the chance of first-attempt SVT conversion compared with the standard Valsalva (RR 2.71, 95% CrI 2.26–3.31) and significantly reduced the need for intravenous adenosine (RR 0.64, 95% CrI 0.55–0.73), with no increase in adverse events. The modified Valsalva outperformed both the standard Valsalva and carotid sinus massage across all outcomes measured.
Carotid sinus massage — firm pressure applied to one carotid body for 5–10 seconds — remains an alternative but carries a small risk of stroke in patients with carotid artery disease and is generally avoided in elderly patients without prior carotid imaging.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
When Vagal Tone Triggers Atrial Fibrillation
While vagal tone protects against some arrhythmias, it can paradoxically trigger others. Vagal atrial fibrillation (AF) is a recognised clinical subtype that typically affects younger men without structural heart disease, often endurance athletes. It tends to occur at rest, after meals, or during sleep — times when parasympathetic tone is highest.
The mechanism involves acetylcholine-activated potassium channels (IKACh) in the atrial tissue. When vagal stimulation is high, these channels shorten the atrial effective refractory period — the minimum time the tissue needs before it can conduct another electrical impulse. This shortening is most pronounced in the pulmonary veins and posterior left atrium, which are the same regions where AF most commonly originates. The shorter refractory period makes it easier for re-entrant electrical wavelets to sustain themselves, providing the substrate for fibrillation.
A 2023 review in Frontiers in Cardiovascular Medicine noted that self-reported vagal triggers account for roughly 6–38% of AF episodes across studies, depending on the population. The reviewers emphasised that vagal and adrenergic AF are best understood as extremes of a spectrum, with many patients showing mixed autonomic features. Machine learning models using HRV features can now predict AF onset minutes before it occurs, which the authors suggested could eventually support wearable-based real-time monitoring and intervention.
VNS for Heart Failure: A Mixed Record
The logic of using vagus nerve stimulation (VNS) to treat heart failure is straightforward: heart failure is characterised by chronic sympathetic overactivation and vagal withdrawal, so restoring vagal tone should improve cardiac function. Three major trials have tested this hypothesis with implanted VNS devices, and the results have been sobering.
ANTHEM-HF (60 patients) showed improvements in left ventricular ejection fraction (LVEF rising from 32.4% to 37.2% over 6 months), quality of life, and exercise capacity. However, it was small, unblinded, and uncontrolled — and the LVEF gain fell within typical measurement variability of about 5%.
NECTAR-HF, a blinded, sham-controlled trial, was negative. It showed no improvement in functional measures compared with sham stimulation. Investigators suggested the stimulation amplitude may have been too low to engage the relevant vagal fibres.
INOVATE-HF was the definitive test — a large randomised trial of 707 patients with chronic heart failure (LVEF below 40%, NYHA Class III) across 85 centres. The primary composite endpoint of death or first worsening heart failure event occurred in 30.3% of VNS patients versus 25.8% of controls (HR 1.14, p=0.37) — no benefit. Mortality trended numerically worse in the stimulation group, though not significantly. Quality of life and functional measures did improve with VNS, but without hard-endpoint benefit, the therapy was not established as effective for heart failure.
Current research has shifted toward non-invasive approaches. Active clinical trials are investigating transcutaneous auricular VNS (taVNS) in heart failure, which avoids the risks of surgical implantation while potentially offering enough vagal activation to improve autonomic balance. Closed-loop VNS systems that adjust stimulation in response to real-time cardiac signals are also under investigation, aiming to deliver more physiologically appropriate dosing than the fixed-schedule stimulation used in earlier trials.
Cardiac Autonomic Neuropathy
The vagus nerve’s cardiac fibres are vulnerable to damage from metabolic disease, aging, and chronic inflammation. Cardiac autonomic neuropathy (CAN) — where the autonomic nerves serving the heart are progressively damaged — is one of the most clinically significant consequences of vagus nerve dysfunction.
Diabetes is the most common cause. In diabetic CAN, chronically elevated blood glucose damages the small nerve fibres of the vagus, typically affecting the longer parasympathetic fibres first (because length-dependent neuropathy hits the longest nerves earliest, and the vagus is the body’s longest cranial nerve). Early CAN manifests as reduced HRV and loss of respiratory sinus arrhythmia — often detectable before any symptoms appear. As it progresses, resting heart rate rises (because the vagal brake is weakened), exercise tolerance drops, and the risk of silent myocardial ischaemia increases because the vagal afferent fibres that would normally transmit chest pain signals are damaged.
CAN is associated with a significantly increased risk of cardiac mortality. The heart rate deep breathing (HRDB) test — measuring the difference in heart rate between deep inhalation and exhalation — is one of the earliest clinical markers, with a normal response of 15+ bpm variation in young adults, declining with age.
Beyond diabetes, aging itself reduces cardiac vagal tone. RMSSD and HF-HRV decline progressively from the third decade onward. Obesity, sedentary behaviour, and chronic psychological stress all accelerate this decline through inflammatory pathways that damage vagal nerve fibres.
Protecting Your Cardiac Vagal Tone
The evidence for maintaining cardiac vagal tone centres on consistent, evidence-based lifestyle practices. Regular aerobic exercise is the most robust intervention — it increases resting vagal tone and HRV across dozens of trials and meta-analyses. The effect is dose-dependent: more consistent exercise produces greater vagal adaptation, though even moderate-intensity walking several times per week produces measurable HRV improvements within weeks.
Slow-paced breathing (around 6 breaths per minute) activates the baroreflex resonance frequency at approximately 0.1 Hz, maximising respiratory sinus arrhythmia and providing a direct vagal training stimulus. HRV biofeedback protocols built around this breathing rate have shown improvements in resting vagally mediated HRV in randomised controlled trials.
Managing blood glucose, maintaining a healthy body weight, limiting alcohol consumption, and prioritising sleep all protect vagal fibres from the metabolic and inflammatory damage that drives CAN. For those with diabetes, early screening with simple bedside tests like the HRDB test can catch vagal decline before it becomes symptomatic, allowing for earlier intervention.
Want to understand the complete picture of how your vagus nerve influences your heart, immune system, gut, and mental health? The “My Vagus Nerve & Me” eBook covers the science of vagal function and practical strategies for supporting it through diet, lifestyle, and stimulation techniques. Get My Vagus Nerve & Me eBook and take the first step toward better cardiovascular health.




